STRONG RESEARCH ACQUISITIONS JOIN QUICK DIVIDEND SLEUTH REASONABLE BOUGHT VITAL STATISTICS JOHNSON PFIZER LAST RECENT BLOCKBUSTER MAJOR BLUE CHIP DEVELOPED ADMIRATION STOCKS EARLY YEARS NEVER PURCHASE PRICE INVESTMENT CLUB SHARES SPLIT GROW AT THAT POINT TRACK TRADED BILL CLINTON PRESIDENT CLINTON ADMINISTRATION HEALTHCARE REFORM CAUSING FEAR UNIVERSAL HEALTHCARE GOVERNMENT REGULATION HURT DRUG PHARMACEUTICAL COMPANIES TRUE BLUE BE 200 STOCK ROSE BIT OVER TIME SOLD FUND STOCK SPLIT THE NEXT IN AUGUST SPECIAL DEEP FREEZE SEVEN FULL CUT THE GREAT RECESSION RAISE UNTIL DECEMBER FLAT PERIOD INTEREST CLOSED POSITION INCOME BEGINNINGS FREEZE RAISED CONSIDER PUTTING WATCH PREPARATION PULLED SPREADSHEETS DISCOVERED YIELD THE POSITION THIS WAS VOCATIONAL REDUCED NUMBER HOLDINGS SHIFT APPROACH TURNING POINT FOCUS FINANCIAL LOWELL INVESTORS STANDARD CREDIT RATINGS MEASURE COLUMN SPREADSHEET CREDIT RATING FOR EACH ALPHA BOB WELLS CREDIT RANKING MILLER CHOWDER HIGHER QUESTION INSPIRED THE COURSE CONCERN FOR WHAT AGING BULL MARKET DESIRE EMPHASIS GAVE GREATER APPRECIATION RARE IF I HAD PRIORITY MONTHS DOUBT PRESENT THE CURRENT BASIS CLOSING PRICE APRIL 21 THE ANNUAL RANGE HIGH PRICE INVESTMENT THESIS RESPECT COMPANY COMES MANY YEARS WATCHING SOMETIMES BALANCE SHEET AFTER 7 MANAGEMENT AFFIRM SOLID PIPELINE DRUGS COMPLEMENT GOOD CHART SHOWS THE PRICE RATHER MIGHT LEAD BELIEVE GRAPH THE HIGH SEEKING ALPHA POSSIBLE TARGET MEANS EAGER ADDING CUSTOM ALERTS HELP ME KEEP UP TARGETS HERE LOGO KENNETH CHAIRMAN OF THE BOARD CHIEF EXECUTIVE OFFICER PREVIOUSLY EXECUTIVE VICE PRESIDENT PRESIDENT OF GLOBAL HUMAN HEALTH GENERAL COUNSEL SENIOR VICE PRESIDENT CEO KEN FRAZIER INTRODUCTION TO PROXY STATEMENT MAY 23RD ANNUAL MEETING SHAREHOLDERS MISSION SAVE IMPROVE KEYTRUDA FOUNDATIONAL MEDICINE INCREASE UNDERSTANDING POTENTIAL TUMOR SCIENTISTS NOVEL THERAPEUTIC PRESSING GLOBAL HEALTH ANTIBIOTIC RESISTANCE AREAS HOSPITAL ACUTE CARE ANIMAL MOMENTUM PRODUCT DIABETES FRANCHISE SHOW VOLUME COMPETITION PRICING ANIMAL HEALTH COMPANION BRAVECTO FLEA TICK ONGOING GARDASIL 9 HPV VACCINE ZEPATIER HEPATITIS BRIDION NEUROMUSCULAR BLOCKADE REVERSAL CUSTOMERS RECOGNIZE VALUE MEDICINES REALITIES HEALTHCARE FUTURE DEPENDS THE FLOW OF REMAINS INVEST INTERNAL DISCOVER DEVELOP TRANSFORMATIONAL CREATE SHAREHOLDER VALUE CONTINUE SEEK THE RIGHT EXTERNAL SCIENTIFIC OPPORTUNITIES VALUATION SAYING MUST FOCUSED DRIVING THE PERFORMANCE CORE BUSINESS EXECUTING MAXIMIZE SUSTAIN STATEMENT OUT IN MY MIND COMMENT EARNINGS CALL CONSOLIDATION TYPE MERGER SEEN INDUSTRY ELABORATION QUOTE EARNINGS PRESS RELEASE DEVELOPMENT TOP PRIORITY WE ARE THE BEST SCIENCE LICENSING GERMAN ONE NORTH AMERICAN FRIEDRICH JACOB PHARMACY GERMANY ANGEL MERCK KGAA ALSO KNOWN AS MERCK GROUP THE COMMERCIAL MORPHINE HOLDS RIGHTS NAME EXCEPT WHERE IT KGAA CHEMICAL COMPANY PUBLIC COMPANY FRANKFURT STOCK EXCHANGE TICKER SYMBOL MERCK FAMILY CONTROLS THE NORTH AMERICAN SUBSIDIARY WORLD WAR ITS AMERICAN SEIZED INDEPENDENT AFTER THE WAR GEORGE MERCK OUTSIDE NORTH BUSINESS SHARP REFERENCES ARTICLE BELL LABS VITAMIN PENICILLIN PREVENT THE POULTRY DISEASE COCCIDIOSIS THE US CANADA MERGED PHARMACEUTICAL COMPANY CHEMICAL MANUFACTURING SALES MARKETING EXPERTISE MEASLES VACCINE MUMPSVAX MUMPS VACCINE ACQUIRED CALGON LEADING WATER TREATMENT CHEMICALS MERUVAX II RUBELLA VACCINE LABORATORIES MANUFACTURER VACCINE MUMPS RUBELLA FDA APPROVAL SINEMET CARBIDOPA SYMPTOMS PNEUMOVAX STATIN FAMILY FDA CONTAINMENT PHARMACEUTICAL CARE LAUNCHED GENOME RESEARCH INSTITUTE JOINT VENTURE COMBINE POULTRY GENETICS GARDASIL HUMAN PAPILLOMAVIRUS VACCINE BILLION ALLERGY CLARITIN PLUS VYTORIN BRAIN TUMOR MECTIZAN DONATION 25TH ANNIVERSARY COMMUNITIES HEPATITIS C ACQUISITION BELSOMRA CANCER DRUG CUBIST PHARMACEUTICALS STUDY GAAP EARNINGS PER SHARE RESEARCH REPORT GAIN CONSUMER CARE LIFTING PAGE ANNUAL REPORT IMPACT COSTS RESTRUCTURING CERTAIN CONNECTION FIND HELPFUL LOOK OPTIONS BELOW GLIMPSE THE PAST WONDERED WHETHER DECADE EARNINGS GROWTH EXPANSION THE ANSWER THE YEARS AVERAGED MULTIPLE IF YOU COMPLETE AVERAGE HIGH ENTIRE VIRTUALLY BUBBLE ABOVE SEEMS TO BE TO TABLE THOSE YEARS TREND ESTIMATES INVESTING RESEARCH DATA DEBT COMPARISON DATA THE DIFFERENCE THE MORE PARTS THE TABLE AT THE BOTTOM FIVE YEARS SIMPLY SAFE SAFETY SCORE SOMEWHAT LESS WEAKER DIVIDEND YIELD THOUSANDS SHARES OUTSTANDING CAPITAL PREVIOUS DRUG PIPELINE BLACK CORAL APRIL 4 WRITING REVIEW DIABETES TREATMENT RIVAL THE TREATMENT REDUCE BLOOD SUGAR PROMOTE WEIGHT LOSS LOWER BLOOD PRESSURE POPULATION BLOCKBUSTER DRUG POTENTIALLY HALF ALREADY IN PHASE DORAVIRINE CHALLENGE PREZISTA REACHED EMERGE REVENUE GENERATOR SHARE JOSH ARNOLD APRIL 11 COUNT SPENT ABLE FLOAT ISSUE DOLLARS SORT OF FACT ZERO ENOUGH HANDED PEOPLE COMMON CURRENT VANTAGE HEADS NATURALLY DOMINATE MOLECULES GLAXOSMITHKLINE FOLLOW NINE OFFERING ANALYSIS SUGGESTS DOUBLE SUCCESS VERSUS LIKES SQUIBB ASTRAZENECA COHORT FORECAST ACCOUNT PRESCRIPTION DRUG ONCOLOGY HUGE PROPORTION RAKE THE THIRD SELLING CONCLUSION RATE HO